Skip to main content

Abstract

If depression is associated with apathy, then they should be expressed together in different dementia syndromes and should co-occur at varying levels of disease severity. The authors performed a cross-sectional comparison of neuropsychiatric symptoms in 30 Alzheimer's disease, 28 frontotemporal dementia, 40 Parkinson's disease, 34 Huntington's disease, and 22 progressive supranuclear palsy patients, using a standardized rating scale (the Neuropsychiatric Inventory). Apathy did not correlate with depression in the combined sample; apathy (r= –0.40, P<0.0001), but not depression, correlated with lower cognitive function as measured by the Mini-Mental State Examination. The relationship of apathy to depression also varied across diagnostic groups. Apathy is a specific neuropsychiatric syndrome that is distinct from depression. Distinguishing these two syndromes has therapeutic implications.
Apathy is defined as diminished motivation not attributable to decreased level of consciousness, cognitive impairment, or emotional distress.1 Depression involves considerable emotional distress, evidenced by tearfulness, sadness, anxiety, agitation, insomnia, anorexia, feelings of worthlessness and hopelessness, and recurrent thoughts of death.2 Traditional diagnostic nomenclature and measures of depression, including the DSM-IV2 and the Hamilton Rating Scale for Depression (Ham-D),3 treat apathy as an aspect of depression, but it may be a discriminable clinical construct that requires a different approach to treatment in some patients.47
Marin et al.7 evaluated patients with Alzheimer's disease (AD), stroke, and major depression by using the Apathy Evaluation Scale8 and the Ham-D. They found that the relationship between apathy and depression varied among diagnostic groups. Apathy and depression were significantly correlated within groups, although absolute levels of apathy and depression varied considerably. Alzheimer's disease patients frequently had high apathy and low depression scores, whereas patients with left hemisphere stroke or major depression frequently had high depression with low apathy scores. Patients with right hemisphere stroke composed the only group that had equal levels of the two symptoms, and it was the only group in which apathy and depression were not correlated. The authors suggested that apathy and depression are clinically distinct neuropsychiatric syndromes.
Neurodegenerative disorders facilitate the study of apathy and depression because they produce demonstrable brain pathology and are frequently associated with neuropsychiatric symptoms.5,913 The Neuropsychiatric Inventory (NPI)14 was designed to assess neuropsychiatric symptoms in dementing illnesses and includes separate subscales for apathy and depression. In two previous studies, we found that patients with frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP) could be discriminated from patients with AD by their more severe apathy and relatively less depression.9,11 We hypothesized that apathy or lack of emotion may be different from depression and speculated that the two symptoms may be produced by different neuroanatomical or neurochemical substrates and would be differentially manifested in a variety of neurologic disorders.

METHODS

Subjects

A total of 154 patients were seen at four academic centers. Study participation required informed consent from both the patient and the caregiver.
Thirty AD patients and 28 FTD patients presented to a dementia clinic at the University of California at Los Angeles, University of California at Los Angeles-Harbor Medical Center, or West Los Angeles Veterans Affairs Medical Center. All 30 AD patients and 22 of the FTD patients have been previously described.9 Probable AD was diagnosed on the basis of criteria established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).15 Frontotemporal dementia was diagnosed on the basis of criteria developed by the Lund and Manchester groups.16
Forty Parkinson's disease (PD) patients were referred to a movement disorders clinic at the University of California at Los Angeles for pallidotomy surgery due to the on-off syndrome, intractable tremor, or bradykinesia on maximum doses of anti-PD medications. Patients were screened by two neurologists and a neurosurgeon. Inclusion criteria included a history indicative of idiopathic PD, including two of the four cardinal signs (rest tremor, rigidity, akinesia/bradykinesia, and gait disturbance/postural instability) and a clear history of responsiveness to levodopa.
Twenty-two patients with PSP were seen at a National Institute of Neurological Disorders and Stroke (NINDS) outpatient clinic and have been previously described.11 All PSP patients met the Blin criteria for probable PSP.17,18
Thirty-four Huntington's disease (HD) patients presented to a specialty clinic at the University of California, San Diego, and all had the typical choreiform movement disorder plus at least one first-degree relative who also had HD.
Patients were screened for chronic mental illness, head trauma, cerebrovascular disease, extrapyramidal disorders other than those described, vitamin deficiency, hypothyroidism, syphilis, and other medical conditions. Not all patients with HD, PSP, and PD had sufficient memory impairment to meet the DSM-IV criteria for dementia; however, they all had degenerative brain diseases as defined by their clinical diagnoses. Our primary focus was not on the level of dementia, but on the relationship of apathy and depression. Secondary analyses examined the relationship of these symptoms to cognitive impairment.

Assessment

Behavioral data were collected during caregiver interviews using the NPI. This instrument assesses 10 behaviors occurring in dementing illnesses, including delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, and aberrant motor behavior (including pacing, rummaging, and compulsions). A frequency rating (1–4) multiplied by a severity rating (1–3) produces a subscale score for each behavior, and summation of subscale scores produces the total NPI score. Another approach to analysis was also used in which we assigned 0 to mean absence and 1 or more to mean presence of the symptom. The NPI has been shown to be valid when compared with a variety of other diagnostic approaches and to have high interrater and test-retest reliability.14 A training videotape and scripted questions were used to ensure cross-site reliability.
The apathy subscale includes items such as showing loss of interest, lacking motivation, less spontaneous, less affectionate, less enthusiastic, lacking in emotions, and not caring about doing new things. The depression subscale includes items such as sad, depressed, tearful, in low spirits, feeling like a failure, hopeless about the future, feeling like a burden, and wishing for death. The depression subscale has no items related to apathy and has been shown to correlate strongly with the Hamilton depression scale.14 The apathy subscale has no items related to sadness.
Cognitive function was assessed with the Mini-Mental State Examination (MMSE).19 A perfect score on the MMSE is 30, and decreasing scores indicate more severe cognitive impairment. The NPI and MMSE were generally administered on the same day.

Data Analysis

The two central issues of the study were 1) how these two symptoms were related to each other and 2) whether or not their relationship was consistent across different dementia syndromes. Spearman correlations were determined for all 10 of the NPI subscale scores and the total MMSE score. A separate matrix was generated for each of the five dementia groups and for the total combined group. A Kruskal-Wallis one-way analysis of variance (ANOVA) on the mean subscale scores was used to determine group differences in the severity of depression and apathy. Analyses are exploratory, and a 0.5 level of significance was accepted as meaningful.

RESULTS

Clinical characteristics of the 154 patients are presented in Table 1. There were almost equal numbers of men and women in the FTD and HD groups, but there were more women in the AD group and more men in both the PD and PSP groups. The AD group was on average about 10 years older than the FTD, PD, and PSP groups and 30 years older than the HD group. MMSE scores were similar in AD and FTD, and these two groups had MMSE scores 10 points lower than the PD, HD, and PSP groups.
The severity of apathy and depression differed significantly among groups (Table 1). A Kruskal-Wallis one-way ANOVA was used to compare mean NPI subscale scores among groups. Significant differences were found across the four groups, with PD and HD patients having the least severe apathy and the most severe depression (Figure 1).
The frequency of apathy and depression and the relationship between the two symptoms varied across diagnostic groups. A large number of AD patients and even more FTD and PSP patients had apathy without depression, whereas many PD and HD patients had depression without apathy. All diagnostic groups had more patients with one or the other symptom than with both symptoms. The disparity between apathy and depression was particularly dramatic in patients with PD and PSP. Few PD patients had apathy alone (n=2; 5%) compared with the number who had depression alone (11; 28%) or depression plus apathy (11; 28%), and few PSP patients had depression, but they had a high frequency of apathy. Of 22 patients with PSP, 17 (77%) had apathy alone,11 1 had depression, and 3 had depression plus apathy (Table 1).
Apathy did not correlate with depression in the combined sample of dementia patients (r=–0.11, P=0.18). There was a nonsignificant negative correlation in the FTD (r=–0.23, P=0.23) and HD (r=–0.15, P=0.40) groups, and there was a nonsignificant positive correlation in the AD group (r=0.26, P=0.16). The PD group was the only dementia group to show a significant correlation between the two symptoms (r=0.34, P=0.03; Table 2). Thus, the pattern of correlation between apathy and depression differed across diagnostic groups, and the presence of one did not predict the presence of the other.
The NPI measures eight neuropsychiatric symptoms in addition to apathy and depression. Some of these symptoms correlated with apathy and other, different symptoms correlated with depression. In the total sample, apathy correlated with disinhibition and aberrant motor behavior, and depression correlated with anxiety, agitation, irritability, and hallucinations (Table 2).
Apathy was correlated with lower cognitive function as measured by the MMSE in the total sample (r= –0.40, P<0.0001), in the FTD group (r= –0.38, P<0.05), and in the HD group (r= –0.35, P<0.05). The AD and PD groups had a trend toward lower cognitive function with increased apathy, and the PSP group had no correlation between apathy and cognitive function. Apathy was not correlated with advancing age.
Depression had no significant correlation with MMSE scores in the combined sample. In AD and PD, there were nonsignificant trends toward a relationship between depression and lower cognitive function. FTD and HD patients showed nonsignificant trends toward relationships between depression severity and better cognitive function, and there were too few PSP patients with depression to support a meaningful analysis.

DISCUSSION

Apathy is highly prevalent in neurodegenerative diseases,5,913 and this study supports and extends findings from the few previous studies addressing the issue of apathy and depression as independent clinical phenomena.5,7,11,20 Unlike the Ham-D used in many previous studies, the depression subscale of the NPI includes no apathy-related items, and the apathy subscale does not have depression-related questions. We found no correlation between apathy and depression in 154 patients with five neurodegenerative disorders. Furthermore, the two symptoms were associated with other neuropsychiatric symptoms in dissimilar ways. Apathy was associated with disinhibition and aberrant motor behavior; depression was associated with anxiety, agitation, irritability, and hallucinations. Apathy and disinhibition may seem like mutually exclusive behaviors, but both are mediated by frontal lobe systems and they are frequently seen together, especially in patients with FTD. Also, the problem behaviors that lead to management difficulties or reduced functional capacity may be primarily related to frontal lobe dysfunction, and previous studies have found that apathy is associated with these symptoms.21,22
In this and previous studies, apathy was significantly correlated with increased cognitive impairment (as measured by the MMSE) in AD and PD,5,13,20,23 but not in PSP11 or HD.22 The relationship between depression and cognitive function in dementia is controversial. Some studies have found an association between depression and more severe cognitive impairment,24 but others have not.25 We found no consistent relationship between depression and cognition in the total sample or in individual diseases. However, the MMSE does not adequately test frontal lobe function, which is frequently impaired in many dementing disorders, and does not provide a valid measure of this part of cognitive decline.
The relationship between apathy and depression appears to be disease-specific. AD, FTD, and PSP had more prevalent and severe apathy, whereas PD and HD had more prevalent and severe depression. PSP patients showed the most frequent and severe apathy and the least depression. One previous study that used different measures of apathy and disease severity found that HD patients were more severely apathetic than AD patients.22
Anatomical localization of regional dysfunction associated with apathy and depression appears to overlap considerably. Depression is reported to be more frequent when focal lesions are anterior and left sided.26 This finding is similar but not identical to findings from metabolic studies in younger patients showing that major depression is associated with frontal, and especially left frontal, hypometabolism.27 Parkinson's disease with depression is associated with reduced glucose metabolism in the inferior frontal28 and medial prefrontal cortex.29 Paralimbic areas such as orbital-inferior prefrontal and temporal cortex have also been implicated in depression in patients with HD.30 Apathy results from damage to medial prefrontal, anterior cingulate, and anterior temporal paralimbic areas, especially the amygdala and related subcortical structures.3133 Apathy in AD patients has been correlated with frontotemporal hypoperfusion in one study23 and with right temporoparietal hypoperfusion in another.21 Apathy may also occur with strokes that involve the posterior limb of the internal capsule.20 Apathy has only recently been the focus of investigation, and there may be several forms of apathy mediated by a network of related structures. The anatomical correlates of apathy require further investigation, but the observations here suggest that the frontal regions involved in FTD and the diencephalic structures affected in PSP are particularly relevant.
Some of the overlap reported between depression and apathy may be due to the use of depression instruments that contain apathy items. Another possible explanation is that similar circuits could be involved in both symptoms but could differ in degree of neurotransmitter involvement among different disorders. Serotonergic agents frequently relieve depression but may increase apathy, whereas dopaminergic agents may relieve apathy34,35 but are ineffective as antidepressants; in acetylcholine-deficient diseases such as AD, a cholinomimetic agent may be useful in reducing apathy, but it does not affect mood.36 One potential explanation for the differential therapeutic responses of depression and apathy is that depression results when an imbalance in paralimbic neurotransmitter function results in excessive negative emotion, whereas apathy occurs when the cortex is functionally disconnected from relevant paralimbic input.
Limitations and strengths of this study should be recognized. First, behavioral assessment was a primary goal in the collection of these data, but the specific hypotheses presented here were not prospectively stated and the analyses are post hoc. Second, depression and apathy are subjective human experiences, and caregiver informant strategies employed by the NPI may not be entirely accurate—although there is evidence to suggest that caregivers are able to provide valid ratings of depression and apathy.8,37 Third, the PD, HD, and PSP patients had significantly less cognitive impairment, which could account for some of the differences that we described as disease-specific. Fourth, psychotropic medications may cause apathy and depression, and we cannot ensure that some of our patients were not taking them; however, these assessments were generally done on the initial visit prior to drug therapy. Finally, we do not have autopsy data to confirm our diagnostic accuracy.
The study is strengthened by the presence of a large group of patients with neurodegenerative disorders and a wide variation in the clinical and pathological expression of their illnesses, which allows us to draw conclusions about the relationship between apathy and depression in the presence of differentially impaired neural pathways. In addition, the use of a reliable and valid instrument that separates the two constructs allows for a meaningful comparison.
We conclude that apathy is common in neurodegenerative diseases and is separable from depression. It may be treatable with dopaminergic or cholinergic medications, and its presence should be sought during the routine course of a neuropsychiatric evaluation. Apathy should not be ascribed to depression, and the diagnosis of depression should be based on symptoms of sadness and feelings of helplessness, hopelessness, and worthlessness.

ACKNOWLEDGMENTS

This project was supported by a Department of Veterans Affairs Neuroscience Fellowship, a National Institute on Aging Alzheimer's Disease Center grant (AG10123), and the Sidell-Kagan Research Fund.
FIGURE 1. Comparison of mean Neuropsychiatric Inventory (NPI) subscale scores for apathy and depression in each diagnostic category. Kruskal-Wallis 1-way analyses of variance: *χ2=47.32, df=4, P<0.00001; **χ2=20.92, df=4, P<0.001. See Table 1 for abbreviations.
TABLE 1.
TABLE 2.

References

1.
Marin RS: Differential diagnosis and classification of apathy. Am J Psychiatry 1990; 147:22–30
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington, DC, American Psychiatric Association, 1994
3.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62
4.
Marin RS, Firinciogullari S, Biedrzycki RC: The sources of convergence between measures of apathy and depression. J Affect Disord 1993; 28:117–124
5.
Starkstein SE, Mayberg HS, Preziosi TJ, et al: Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:134–139
6.
Marin RS: Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3:243–254
7.
Marin RS, Firinciogullari S, Biedrzycki RC: Group differences in the relationship between apathy and depression. J Nerv Ment Dis 1994; 182:235–239
8.
Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the apathy evaluation scale. Psychiatry Res 1991; 38:143–162
9.
Levy ML, Miller BL, Cummings JL, et al: Alzheimer disease and frontotemporal dementias: behavioral distinctions. Arch Neurol 1996; 53:687–690
10.
Mega MS, Cummings JL, Fiorello T, et al: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130–135
11.
Litvan I, Mega MS, Cummings JL, et al: Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996; 47:1184–1189
12.
Bozzola FG, Gorelick PB, Freels S: Personality changes in Alzheimer's disease. Arch Neurol 1992; 49:297–300
13.
Devanand DP, Brockington CD, Moody BJ, et al: Behavioral syndromes in Alzheimer's disease. International Psychogeriatrics 1992; 4(suppl)2:161–184
14.
Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308–2314
15.
McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939–944
16.
Brun A, Englund B, Gustafson L, et al: Consensus statement: Clinical and neuropathological criteria for frontotemporal dementia: the Lund and Manchester groups. J Neurol Neurosurg Psychiatry 1994; 57:416–418
17.
Litvan I, Agid Y, Jankovic J, et al: Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996; 47:1–9
18.
Blin J, Baron JC, Dubois B, et al: Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990; 47:747–752
19.
Folstein MF, Folstein SE, McHugh PR: “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198
20.
Starkstein SE, Fedoroff JP, Price TR, et al: Apathy following cerebrovascular lesions. Stroke 1993; 24:1625–1630
21.
Ott BR, Noto RB, Fogel BS: Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study. J Neuropsychiatry Clin Neurosci 1996; 8:41–46
22.
Paulsen JS, Stout JC, DeLaPena J, et al: Frontal behavioral syndromes in cortical and subcortical dementia. Assessment 1996; 3:327–337
23.
Craig AH, Cummings JL, Fairbanks L, et al: Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996; 53:1116–1120
24.
Cooper JK, Mungas D, Weiler PG: Relation of cognitive status and abnormal behaviors in Alzheimer's disease. J Am Geriatr Soc 1990; 38:867–870
25.
Sultzer DL, Levin HS, Mahler ME, et al: Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale. J Am Geriatr Soc 1992; 40:549–555
26.
Starkstein SE, Robinson RG: Depression in cerebrovascular disease, in Depression in Neurologic Disease, edited by Starkstein SE, Robinson RG. Baltimore, Johns Hopkins University Press, 1993, pp 28–49
27.
Baxter LR, Schwartz JM, Phelps ME, et al: Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989; 46:243–250
28.
Mayberg HS, Starkstein SE, Sadzot B, et al: Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990; 28:57–64
29.
Ring HA, Bench CJ, Trimble MR, et al: Depression in Parkinson's disease: a positron emission study. Br J Psychiatry 1994; 165:333–339
30.
Mayberg HS: Neuroimaging studies of depression in neurologic disease, in Depression in Neurologic Disease, edited by Starkstein SE, Robinson RG. Baltimore, Johns Hopkins University Press, 1993, pp 186–216
31.
Cummings JL: Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50:873–880
32.
Duffy JD: The neural substrates of motivation. Psychiatric Annals 1997; 27:24–29
33.
Marin RS: Apathy: concept, syndrome, neural mechanisms, and treatment. Seminars in Clinical Neuropsychiatry 1996; 1:304–314
34.
Marin RS, Fogel BS, Hawkins J, et al: Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995; 7:23–30
35.
Watanabe MD, Martin EM, DeLeon OA, et al: Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci 1995; 7:502–504
36.
Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996; 9:1–6
37.
Logsdon RG, Teri L: Depression in Alzheimer's disease patients: caregivers as surrogate reporters. J Am Geriatr Soc 1995; 43:150–155

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 314 - 319
PubMed: 9706539

History

Published online: 1 August 1998
Published in print: August 1998

Authors

Details

Morgan L. Levy, M.D.
Received June 12, 1997; revised August 13, 1997; accepted August 14, 1997. From the Departments of Psychiatry/Biobehavioral Sciences and Neurology, University of California–Los Angeles School of Medicine, the West Los Angeles Veterans Affairs Medical Center Psychiatry Service, and Harbor-UCLA Medical Center, Los Angeles, California; the Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa; and the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.
Jeffrey L. Cummings, M.D.
Received June 12, 1997; revised August 13, 1997; accepted August 14, 1997. From the Departments of Psychiatry/Biobehavioral Sciences and Neurology, University of California–Los Angeles School of Medicine, the West Los Angeles Veterans Affairs Medical Center Psychiatry Service, and Harbor-UCLA Medical Center, Los Angeles, California; the Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa; and the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.
Lynn A. Fairbanks, Ph.D.
Received June 12, 1997; revised August 13, 1997; accepted August 14, 1997. From the Departments of Psychiatry/Biobehavioral Sciences and Neurology, University of California–Los Angeles School of Medicine, the West Los Angeles Veterans Affairs Medical Center Psychiatry Service, and Harbor-UCLA Medical Center, Los Angeles, California; the Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa; and the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.
Donna Masterman, M.D.
Received June 12, 1997; revised August 13, 1997; accepted August 14, 1997. From the Departments of Psychiatry/Biobehavioral Sciences and Neurology, University of California–Los Angeles School of Medicine, the West Los Angeles Veterans Affairs Medical Center Psychiatry Service, and Harbor-UCLA Medical Center, Los Angeles, California; the Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa; and the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.
Bruce L. Miller, M.D.
Received June 12, 1997; revised August 13, 1997; accepted August 14, 1997. From the Departments of Psychiatry/Biobehavioral Sciences and Neurology, University of California–Los Angeles School of Medicine, the West Los Angeles Veterans Affairs Medical Center Psychiatry Service, and Harbor-UCLA Medical Center, Los Angeles, California; the Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa; and the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.
Anne H. Craig, M.D.
Received June 12, 1997; revised August 13, 1997; accepted August 14, 1997. From the Departments of Psychiatry/Biobehavioral Sciences and Neurology, University of California–Los Angeles School of Medicine, the West Los Angeles Veterans Affairs Medical Center Psychiatry Service, and Harbor-UCLA Medical Center, Los Angeles, California; the Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa; and the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.
Jane S. Paulsen, Ph.D.
Received June 12, 1997; revised August 13, 1997; accepted August 14, 1997. From the Departments of Psychiatry/Biobehavioral Sciences and Neurology, University of California–Los Angeles School of Medicine, the West Los Angeles Veterans Affairs Medical Center Psychiatry Service, and Harbor-UCLA Medical Center, Los Angeles, California; the Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa; and the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.
Irene Litvan, M.D.
Received June 12, 1997; revised August 13, 1997; accepted August 14, 1997. From the Departments of Psychiatry/Biobehavioral Sciences and Neurology, University of California–Los Angeles School of Medicine, the West Los Angeles Veterans Affairs Medical Center Psychiatry Service, and Harbor-UCLA Medical Center, Los Angeles, California; the Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa; and the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share